Corpus ID: 44536205

Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism.

@article{FunckBrentano1989EffectOL,
  title={Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism.},
  author={C. Funck-Brentano and J. Turgeon and R. Woosley and D. Roden},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={1989},
  volume={249 1},
  pages={
          134-42
        }
}
Encainide biotransformation to its active metabolites O-desmethyl encainide and 3-methoxy-O-desmethyl encainide cosegregates with the polymorphic oxidation of debrisoquine. Because quinidine has been reported recently to be a potent inhibitor of the enzyme responsible for this polymorphism (cytochrome P450db1), we tested the hypothesis that quinidine would selectively inhibit encainide metabolism and alter its effects in subjects with the extensive metabolism phenotype for debrisoquine… Expand
The effect of diltiazem on the disposition of encainide and its active metabolites
Effects of encainide and metabolizer phenotype on ventricular conduction during exercise.
Induction of polymorphic 4'-hydroxylation of S-mephenytoin by rifampicin.
...
1
2
3
4
5
...